STAT+: Diseased protein degrader shows mixed results in breast cancer trial
Arvinas and Pfizer's drug vepdegestrant reduced the risk of tumor progression 40% compared to standard treatment for an ESR1-mutated population.
An experimental drug developed by the biotech firm Arvinas and Pfizer — the first in a class of medicines based on a cell’s natural machinery for eliminating diseased proteins — delayed tumor progression in women with a genetically altered form of the most common type of breast cancer, the companies said Tuesday.
In the Phase 3 study, the drug called vepdegestrant achieved the primary efficacy goal in participants with ER-positive, HER2-negative metastatic breast cancer rendered more difficult to treat due to a genetic mutation called ESR1.
However, vepdegestrant was not effective in a larger group of participants with breast cancer lacking the ESR1 mutation.
